Abstract
It is now becoming clear that several papain-like cysteine cathepsins are involved in the pathophysiology of diseases such as osteoporosis, autoimmune disorders, and cancer. Therefore, the development of potent and selective cathepsin inhibitors is an attractive subject for medicinal chemists. New advances have been made for nitrile-based inhibitors, leading to the identification of the cathepsin K inhibitor odanacatib and other candidates with potential for therapeutic use. This review summarizes the development of peptidic and peptidomimetic compounds with an electrophilic nitrile ‘warhead’ as inhibitors of the cysteine cathepsins B, S, L, C, and K. Peptide nitriles have been shown to reversibly react with the active site cysteine under formation of a covalent thioimidate adduct. The structural optimization with respect to the positions P3, P2, P1, P1, and P2 resulted in the identification of potent and selective inhibitors of the corresponding cathepsins. The underlying structure-activity relationships are discussed herein.
Keywords: Cathepsin, covalent modifier, cysteine protease, lysosomotropic property, osteoporosis, peptide nitrile, peptidomimetic, protease inhibitor, thioimidate
Current Topics in Medicinal Chemistry
Title: Development of Nitrile-Based Peptidic Inhibitors of Cysteine Cathepsins
Volume: 10 Issue: 3
Author(s): Maxim Frizler, Marit Stirnberg, Mihiret Tekeste Sisay and Michael Gutschow
Affiliation:
Keywords: Cathepsin, covalent modifier, cysteine protease, lysosomotropic property, osteoporosis, peptide nitrile, peptidomimetic, protease inhibitor, thioimidate
Abstract: It is now becoming clear that several papain-like cysteine cathepsins are involved in the pathophysiology of diseases such as osteoporosis, autoimmune disorders, and cancer. Therefore, the development of potent and selective cathepsin inhibitors is an attractive subject for medicinal chemists. New advances have been made for nitrile-based inhibitors, leading to the identification of the cathepsin K inhibitor odanacatib and other candidates with potential for therapeutic use. This review summarizes the development of peptidic and peptidomimetic compounds with an electrophilic nitrile ‘warhead’ as inhibitors of the cysteine cathepsins B, S, L, C, and K. Peptide nitriles have been shown to reversibly react with the active site cysteine under formation of a covalent thioimidate adduct. The structural optimization with respect to the positions P3, P2, P1, P1, and P2 resulted in the identification of potent and selective inhibitors of the corresponding cathepsins. The underlying structure-activity relationships are discussed herein.
Export Options
About this article
Cite this article as:
Frizler Maxim, Stirnberg Marit, Sisay Tekeste Mihiret and Gutschow Michael, Development of Nitrile-Based Peptidic Inhibitors of Cysteine Cathepsins, Current Topics in Medicinal Chemistry 2010; 10 (3) . https://dx.doi.org/10.2174/156802610790725452
DOI https://dx.doi.org/10.2174/156802610790725452 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Commentary: Gut Microbiota and Brain Function: A New Target for Brain Diseases?
CNS & Neurological Disorders - Drug Targets The Mutual Interaction Between Sleep and Epilepsy on the Neurobiological Basis and Therapy
Current Neuropharmacology Co-Enzyme Q10 to Treat Neurological Disorders: Basic Mechanisms, Clinical Outcomes, and Future Research Direction
CNS & Neurological Disorders - Drug Targets Rufinamide Improves Functional and Behavioral Deficits <i>via</i> Blockade of Tetrodotoxin-Resistant Sodium Channels in Diabetic Neuropathy
Current Neurovascular Research Multiscale Modelling of Relationships between Protein Classes and Drug Behavior Across all Diseases Using the CANDO Platform
Mini-Reviews in Medicinal Chemistry Synthesis and Studies on Anticonvulsant and Antibacterial Activities of 1- Alkyl-4-(4H-1,2,4-triazol-4-yl)piperidine Derivatives
Letters in Drug Design & Discovery Novel Therapeutic Effects of the Anti-Convulsant, Zonisamide, on Parkinsons Disease
Current Pharmaceutical Design Gene Therapy for Neuroprotection and Neurorestoration (Part I)
Current Gene Therapy Design, Synthesis and in silico Studies of New 5-substituted-2-(2-(5-aryl- 1H-1, 2, 4-triazole-3-ylthio) acetyl) Hydrazine Carbothioamide/ Carboxamides for Anticonvulsant Activity
Letters in Drug Design & Discovery Reverse Iontophoretic Extraction of Gabapentin: A Mechanistic Study
Current Drug Delivery Metabolic Drug Interactions Between Antidepressants and Anticancer Drugs: Focus on Selective Serotonin Reuptake Inhibitors and Hypericum Extract
Current Drug Metabolism Synthesis and Evaluation of Anticonvulsant Activities of Pyrazol yl Semicarbazones. Part II
Letters in Drug Design & Discovery The Endocannabinoid System and Pain
CNS & Neurological Disorders - Drug Targets Exploiting the Diversity of the Heat-Shock Protein Family for Primary and Secondary Tauopathy Therapeutics
Current Neuropharmacology Metabotropic GABAB Receptors New Challenges in Drug Design
Current Medicinal Chemistry - Central Nervous System Agents Imidazole: An Essential Edifice for the Identification of New Lead Compounds and Drug Development
Mini-Reviews in Medicinal Chemistry Computer-Aided Drug Discovery and Design Targeting Ion Channels
Current Topics in Medicinal Chemistry Computational Models of Neuronal Biophysics and the Characterization of Potential Neuropharmacological Targets
Current Medicinal Chemistry Melatonin in Autism Spectrum Disorders
Current Clinical Pharmacology Biomedical Application of Polymers: A Case Study of Non-CNS Drugs Becoming CNS Acting Drugs
Central Nervous System Agents in Medicinal Chemistry